MaxCyte Investor Presentation Deck

The EXPERT™ Platform Enabling Non-Viral Cell Engineering ● Launched in 2019 based on MaxCyte's proprietary Flow Electroporation technology and has been optimized for the past 20+ years • Leverages the reversible permeability of the cell membrane in response to an electric charge • Universally delivers molecules, such as nucleic acids, gene-editing tools and proteins, into cells ● Agnostic to cell type, approach (auto/allo) and/or gene manipulation technology Enables customers to use a single platform from concept through to the clinic in a GMP environment • Supported by a robust intellectual property portfolio (150+ patents granted in US and foreign jurisdictions and 95+ patents pending worldwide) EXPERT™ Instrument Portfolio Small/mid-scale RUO AT&™ ● High Performance: >90% transfection efficiencies (depending on cell type and molecule) • >90% cell viabilities Computer-controlled system for reproducible results 9 Full scale RUO STX Flexibility: Single, fully-defined, animal component-free electroporation buffer for all cell types Pre-loaded library of validated, cell-specific protocols ● Scalability - Ability to Transfect: 75,000 to 7 million cells in seconds ● GTX ● Full scale RUO/CGMP Up to 20 billion cells in less than 30 minutes And up to 200 billion cells in less than 30 minutes with the high scale VLX M MaxCyte High Quality: ● Large Scale RUO/CGMP VLX™ TM Sterile, single-use processing assemblies (PAS) Closed, cGMP-compliant, ISO-certified, and CE marked instruments Supported by US FDA Master File and global equivalents © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation